# nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct01824394` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01824394](<https://clinicaltrials.gov/study/NCT01824394>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01824394

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 481 participants.

## Technical summary

Registry record NCT01824394. Randomized; single masking; primary purpose treatment. Start 2013-04-01 (actual); primary completion 2017-11-26 (actual). Results posted on 2018-12-12.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 481 participants (enrolled count; ClinicalTrials.gov record NCT01824394, source copy `cardio:ctgov-nct01824394-2025-02-04`, retrieved 2026-10-26)
- Started: 2013-04-01 (actual) (ClinicalTrials.gov record NCT01824394, source copy `cardio:ctgov-nct01824394-2025-02-04`, retrieved 2026-10-26)
- Primary completion: 2017-11-26 (actual) (ClinicalTrials.gov record NCT01824394, source copy `cardio:ctgov-nct01824394-2025-02-04`, retrieved 2026-10-26)
- Completion: 2017-11-26 (actual) (ClinicalTrials.gov record NCT01824394, source copy `cardio:ctgov-nct01824394-2025-02-04`, retrieved 2026-10-26)
- Results first posted: 2018-12-12 (ClinicalTrials.gov record NCT01824394, source copy `cardio:ctgov-nct01824394-2025-02-04`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01824394-2025-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
- Condition: Atrial Fibrillation
- Intervention (Device): nMARQ Navigation Catheters
- Intervention (Device): NaviStar ThermoCool Catheters
- Lead sponsor: Biosense Webster, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Biosense Webster, Inc. (`cardio:org-biosense-webster-inc`)

## Provenance

Content hash: 7e1f725cd1bdb390dee60f67e71c90bfa9211f5464bcbdd9ae0c711904487038
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
